Halberd

Halberd Net Debt / EBITDA

The Net Debt to EBITDA of Halberd (HALB) as of Oct 11, 2026 is -0.32. In the previous year, Net Debt to EBITDA was -0.09 — a change of 268.70% (lower).

Net Debt / EBITDA

-0.32

YoY

268.70%

Last updated:

Net Debt to EBITDA of Halberd is 2023 -0.32 . Net Debt to EBITDA of Halberd was 2022 -0.09 . It decreases by 268.70% lower compared to the previous year.

The Halberd Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2009
-0.02 USD
Jan 1, 2010
-1.37 USD
Jan 1, 2011
8.67 USD
Jan 1, 2012
12.51 USD
Jan 1, 2016
9.14 USD
Jan 1, 2021
-0.13 USD
Jan 1, 2022
-0.09 USD
Jan 1, 2023
-0.32 USD
The Halberd Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
-0.32+268.70%
-0.09-32.30%
-0.13-101.40%
9.14-26.91%
12.51+44.33%
8.67-734.33%
-1.37+5,389.68%
-0.02-99.70%
-8.18—
Access this data via the Eulerpool API
Get Free API Key

Halberd Stock analysis

What does Halberd do? The Halberd Corp is an American company founded in 1987 and based in New York. It is a high-tech company focused on the development of medical technologies. Since its inception, the company has developed numerous innovative products and technologies that are used worldwide. A significant portion of Halberd Corp's business model focuses on providing medical products and solutions for various diseases. The main divisions of the company are biotechnology and pharmaceuticals, medical respiratory protection, medical technology, and the development of antibodies and diagnostics. Some of the most well-known products of Halberd Corp are the Medical Respiratory Masks, which were of great importance during the COVID-19 pandemic. These masks were developed and distributed worldwide by the company with innovative technology and the highest quality standards. The company has also developed various medical devices such as infusion pumps, blood pressure monitors, and various diagnostic devices that have been used by hospitals and care facilities. Another important business area of Halberd Corp is biotechnology and pharmaceuticals. In this field, the company specializes in developing new drugs and therapies for various diseases. The company has developed a range of proprietary medications that are used in the treatment of various diseases. Halberd Corp is also known for its development of antibodies and diagnostics and offers corresponding test kits. In recent years, Halberd Corp has formed numerous partnerships with other companies and institutions to bring its innovations to the market and market them. The company is also known for its successful joint ventures with other companies in the healthcare sector. Overall, Halberd Corp is an innovative company focused on medical technologies. With its presence in various areas of the healthcare industry, the company is able to develop new products and solutions that have the potential to improve and save lives. Halberd is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Halberd stock

Net Debt to EBITDA of Halberd is -0.32 in 2023.

Net Debt to EBITDA of Halberd changed from -0.09 to -0.32, representing a 268.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Halberd since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Halberd with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API
Get Free API Key

Leverage — Halberd

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Halberd